

# **GO-Dx Corporation (Aust) Ltd**

ACN 673 839 613

## **Consolidated Financial Statements**

For the Year Ended 30 June 2025

# GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Contents

For the Year Ended 30 June 2025

	Page
<b>Consolidated Financial Statements</b>	
Directors' Report	1
Auditor's Independence Declaration under Section 307C of the Corporations Act 2001	18
Consolidated Statement of Profit or Loss and Other Comprehensive Income	19
Consolidated Statement of Financial Position	20
Consolidated Statement of Changes in Equity	21
Consolidated Statement of Cash Flows	22
Notes to the Financial Statements	23
Consolidated Entity Disclosure Statement	56
Directors' Declaration	57
Independent Audit Report	58
Additional Information for Listed Public Companies	62

# GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Directors' Report For the Year Ended 30 June 2025

The directors present their report, together with the consolidated financial statements of the Group, being GO-Dx Corporation (Aust) Ltd ("the Company") and its controlled entities, for the financial year ended 30 June 2025.

The Group was incorporated on 22 December 2023 and as the comparative financial information included, is for the year from incorporation to 30 June 2024.

### Information on directors

The names, qualifications, experience and special responsibilities of each person who has been a director during the year and to the date of this report are:

Dr Kah Meng Lim	(Appointed 15 January 2024)
Qualifications	PhD
Experience	<p>Dr Lim has dedicated over 20 years in the life science research field, including 2 years as a research scientist at the Singapore government funded A*Star research institute and a post-doctorate attachment at the University of Minnesota, USA. His specialty includes researching in stem cells and cancerous diseases. Dr Lim received his PhD in 2002.</p> <p>His work involved cell growth, regulation in cancer, infectious diseases, and biomedicine product development. Experienced Business Catalyst and Accelerator with a demonstrated history of success and exemplary domain knowledge in the biotechnology and biopharmaceutical industry. Strong business development professional skilled in Biotechnology, Life Sciences, Strategic Planning, Business Strategy, and Pharmaceutical Industry.</p> <p>Notable past roles include:</p> <ul style="list-style-type: none"><li>• Metagen Biologics – Founding Chairman, July 2021 to Present</li><li>• Singapore Paincare Holdings (SGX) – Independent Director, Mar 2021 to Present</li><li>• Compass Ventures Inc (TSX-V) – CEO and Director, November 2020 to Present</li><li>• Gene Oasis Bioscientific - Owner and Chairman, 2009 to Present</li><li>• Nanyang Technological University Singapore – Adjunct assistant Professor, 2012 to 2015</li><li>• A*Star Singapore (Agency for Science, Technology and Research) – Research Scientist, 2002 to 2004</li></ul>
Interest in shares and options	63,609,723 fully paid ordinary shares
Special responsibilities	Group Managing Director and Chief Executive Officer Member: Remuneration Committee
Other current directorships in listed entities	Independent Non-Executive Director of Singapore Paincare Holdings Ltd (SGX: FRQ)
Other directorships in listed entities held in the previous three years	N/A

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Report For the Year Ended 30 June 2025

#### Information on directors (continued)

Mr Sah Soon Lim	(Appointed 16 January 2024)
Qualifications	Chartered Surveyor; Chartered Secretary
Experience	<p>Mr Lim is currently Managing Director of charity organisation, Huaxia Cultural Hub Ltd. He also serves as a Director of two family companies, The Kindred Spirit Pte Ltd and Pheng Geck Pte Ltd, providing 24-hour gym services to approximately 2,500 active members.</p> <p>Mr Lim started his career with the Singapore's Housing Development Board as a Junior Officer in 1967, and within a short span of 10 years, he was promoted to a super-scale Officer. Soon after, he was seconded to the Prime Minister's Office to spearhead and complete a national wide community project.</p> <p>In 1995, he was invited by Singapore Chinese Chamber of Commerce &amp; Industry (SCCCI) to serve as its Secretary General as well as the Honorary Secretary General of the then Singapore Federation of Chambers of Commerce &amp; Industry. Since his retirement from SCCCI in 2013, Mr Lim has served as a Member of the Practicing Management Consultants Certification Board in Singapore.</p> <p>Mr Lim also chairs the Membership Affairs Committee of the Singapore Teochew Federation. He also serves as Council Member of Teo Ann Huey Kuan, Member of the TCM Board Disciplinary Investigation Panel, Advisor to World Lin Chamber of Commerce, and Advisor to Federation of World Cultural &amp; Art Society.</p>
Interest in shares and options	6,600,000 fully paid ordinary shares
Special responsibilities	Non-Executive Director Member: Finance Audit Risk Management Committee
Other current directorships in listed entities	N/A
Other directorships in listed entities held in the previous three years	N/A

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Report For the Year Ended 30 June 2025

#### Information on directors (continued)

Mr Cody Blackhurst	(Appointed 1 October 2024)
Qualifications	Member of the Australian Institute for Company Directors Justice of the Peace (Qualified).
Experience	<p>Mr Blackhurst is Australia based and brings considerable knowledge in establishing ongoing relationships with key stakeholders to maximise strategic outcomes.</p> <p>Cody brings commercial and governance expertise from a range of Australian private and public companies. These include terms as international Head of Commodities Trading, and assistant to the Company Secretary of an ASX listed group operating in PR China.</p> <p>He has significant experience in business start-ups, including as founder of a metals trading business and building services company. Cody also co-founded an international online biomechanics enterprise developed and accredited under the S5 principle which is predominantly focussed on elite performance and remedial support.</p>
Interest in shares and options	Nil
Special responsibilities	Non-Executive Director Company Secretary Member: Finance Audit Risk Management Committee Member: Remuneration Committee
Other current directorships in listed entities	N/A
Other directorships in listed entities held in the previous three years	N/A
Mr William Bass	(Appointed 1 October 2024)
Qualifications	B.Econ., CA, MAICD, FCS, FGIA, FInstIB, JP (Qual.) NSX Nominated Advisor GD8 - Responsible Officer
Experience	<p>Mr Bass in Australia based and brings extensive commercial and financial expertise and experience from a range of leading Australian and international private and public companies.</p> <p>He is active in several philanthropic and business innovation ventures.</p>
Interest in shares and options	Nil
Special responsibilities	Non-Executive Director and Chair Member and Chair: Finance Audit Risk Management Committee Member and Chair: Remuneration Committee
Other current directorships in listed entities	N/A
Other directorships in listed entities held in the previous three years	N/A

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Directors' Report For the Year Ended 30 June 2025

### Information on directors (continued)

#### Former Directors:

Mr Justyn Stedwell	(Appointed 22 December 2023 and resigned 8 October 2024)
Mr Matthew Leonard	(Appointed 22 December 2023 and resigned 8 October 2024)

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

### Principal activities and significant changes in nature of activities

The Group is in the medical diagnostics and diagnostics technology sectors of the healthcare industry, pioneering development and innovation with regard to personalised Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular, immunity, anti-ageing, neural health, and specific cancers. The Group operates such business via GO-Dx Singapore, its wholly owned subsidiary incorporated in Singapore.

Specifically, the Group's business is focused on the following activities:

- commercialising its own RNA Mining / Mapping Platform, and development of its microRNA (miRNA) technologies;
- development of scientific methods using miRNA-based diagnostics for cancers;
- undertaking various artificial intelligence (AI) collaborations in the diagnostic space to develop an AI-enabled Platform to augment the RNA Mining / Mapping Platform and RNA Analytical Platform; and
- nutraceutical product supply rights and corresponding distribution rights to market and sell such products throughout various Asian jurisdictions.

There were no significant changes in the nature of the Group's principal activities during the financial year.

### Operating results

The consolidated loss of the Group amounted to \$1,028,531 (2024: \$296,768), after providing for income tax.

### Review of operations

A review of the operations of the Group during the financial year and the results of those operations show that the Group continued to engage in its principal activity, the results of which are disclosed in the attached financial statements.

Operations during the year were specifically focused on progressing its first products and programs, which comprises one comprehensive DNA Health Profiling package, and its first proprietary Vmmune product. The Group continued to build its distribution channels to ensure it meets its sales and revenue targets, and assembling a team to start developing the RNA mining/mapping proprietary technology platform.

During the financial year ended 30 June 2024, the Group had placed deposits of S\$156,500 for its agreed investment of S\$200,000 into Pathomics Health. The balance of the agreed investment was paid during the year ended 30 June 2025. The directors assessed the amount paid and have concluded that it was appropriate to expense the amount of \$233,977 (S\$200,000) in the financial year.

## **GO-Dx Corporation (Aust) Ltd**

ACN 673 839 613

### **Directors' Report** **For the Year Ended 30 June 2025**

#### **Significant changes in state of affairs**

Other than the matters previously disclosed, there were no significant changes in the state of affairs of the Group during the financial year:

#### **Dividends paid or recommended**

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends has been made.

#### **Events after the reporting date**

- i) Following review of the Group's operations, the directors commenced winding up of Go-Dx Philippines Inc., a company incorporated and domiciled in Philippines. This is incomplete at the reporting date.
- ii) The Company entered into a Convertible Note Agreement with Dr KM Lim to provide funding to the Group. The key terms of the Convertible Note Agreement are:  
Term : 1 year to Maturity Date 30 September 2026  
Purpose: working capital support  
Principal : A\$500,000  
Interest: 2% simple per annum on drawn down funds  
Conversion: A\$0.19 per share on principal sum & accrued interest at any time prior to Maturity Date

Except for the above, no other matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

#### **Future developments and results**

Likely developments in the operations of the Group and the expected results of those operations in future financial years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the Group.

#### **Environmental issues**

The Group's operations are not regulated by any significant environmental regulations under a law of the Commonwealth or of a state or territory of Australia.

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Directors' Report

### For the Year Ended 30 June 2025

#### Company secretary

The following person held the position of Company secretary during the financial year:

Mr Bill Pavlovski (1 July 2024 – 4 October 2024)  
Mr Cody Blackhurst (4 October 2024 - present).

#### Meetings of directors

During the financial year, there were 17 meetings of directors (including committees of directors) held. Attendances by each director during the year were as follows:

	Finance Audit Risk Mgt. Committee 2025		Remuneration Committee 2025		Directors' Meetings 2025		Directors' Meetings 2024	
	Number eligible to attend	Number attended	Number eligible to attend	Number attended	Number eligible to attend	Number attended	Number eligible to attend	Number attended
Mr William Bass	2	2	1	1	16	16	-	-
Mr Cody Blackhurst	2	2	1	1	16	16	-	-
Dr Kah Meng Lim	2	2	-	-	17	17	2	2
Mr Sah Soon Lim	-	-	1	1	17	14	2	2
Mr Matthew Leonard	-	-	-	-	3	3	2	2
Mr Justyn Stedwell	-	-	-	-	3	2	2	2

#### Indemnity and insurance of officers and auditors

No indemnities have been given or insurance premiums paid, during or since the end of the financial year, for any person who is or has been an officer or auditor of GO-Dx Corporation (Aust) Ltd.

#### Proceedings on behalf of Company

No person has applied for leave of court under Section 237 of the *Corporations Act 2001* to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Group with leave of the court under Section 237 of the *Corporations Act 2001*.



## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Report For the Year Ended 30 June 2025

#### Non-audit services

The Board of Directors, is satisfied that the provision of non-audit services during the year is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*. The directors are satisfied that the services disclosed below did not compromise the external auditor's independence for the following reasons:

- all non-audit services are reviewed and approved by the audit committee prior to commencement to ensure they do not adversely affect the integrity and objectivity of the auditor; and
- the nature of the services provided do not compromise the general principles relating to auditor independence in accordance with APES 110 *Code of Ethics for Professional Accountants* set by the Accounting Professional and Ethical Standards Board.

The following fees were paid or payable to the external auditors for non-audit services provided during the year ended 30 June 2025:

	2025	2024
	\$	\$
Preparation of investigating accountant's report for IPO	-	28,600
<b>Total</b>	<b>-</b>	<b>28,600</b>

#### Auditor's independence declaration

The auditor's independence declaration in accordance with section 307C of the *Corporations Act 2001* for the year ended 30 June 2025 has been received and can be found on page 17 of the consolidated financial report.

## **Directors' Report**

### **For the Year Ended 30 June 2025**

#### **Remuneration report (audited)**

The remuneration report, which has been audited, outlines the director and executive remuneration arrangements for the Group, in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

Key Management Personnel ("KMP") are those having authority and responsibility for planning, directing and controlling the activities of the Group directly or indirectly, including all directors.

#### **Principles used to determine the nature and amount of remuneration**

The performance of the Group depends upon the quality of its Directors and Executives. To prosper, the Group must attract, motivate and retain highly skilled Directors and Executives. To that end, the Group embodies the following principles in its remuneration framework:

- Provide competitive rewards to attract high calibre executives;
- Focus on creating sustained shareholder value;
- Placing a portion of executive remuneration at risk, dependent upon meeting predetermined performance benchmarks; and
- Differentiation of individual rewards commensurate with contribution to overall results and according to individual accountability, performance and potential.

The Board's policy for determining the nature and amount of remuneration for KMP for the Group is based on the following:

- The remuneration policy is developed and approved by the Board after recommendation from the Remuneration Committee, including professional advice sought from independent external consultants (where applicable).
- All executive KMP receive a base salary (which is based on factors such as length of service and experience), superannuation, fringe benefits and performance incentives, where appropriate.
- Performance incentives (in the form of a cash bonus) are generally only paid once pre-determined key performance indicators (KPIs) have been met.
- Apart from those detailed in this report no other share based/options incentives have been offered to KMP during this reporting year; and
- The Remuneration Committee reviews the remuneration packages annually by reference to the Group's performance, executive performance and comparable information from industry sectors. Proposed remuneration for the ensuing year is considered at each Annual General Meeting.

All remuneration paid to KMP is valued at the cost to the Group and expensed.

KMP or closely related parties of KMP are prohibited from entering hedge arrangements that would have the effect of limiting the risk exposure relating to their remuneration. In addition, the Board's remuneration policy prohibits Directors and KMP from using the Group's shares as collateral in any financial transaction.

#### **Engagement of remuneration consultants**

During the year, the Group did not engage any remuneration consultants.

## **Directors' Report**

### **For the Year Ended 30 June 2025**

#### **Remuneration report (audited) (continued)**

##### **Remuneration structure**

The structure of Non-Executive, Executive Director and Senior Management remuneration is separate and distinct.

##### **A. Non-Executive Director Remuneration**

The Board's policy is to remunerate Non-Executive Directors at market rates for time, commitment and responsibilities. The Remuneration Committee recommends to the Board payments to the Non-Executive Directors and reviews their remuneration annually, based on market practice, duties and accountability. Independent external advice is sought when required. The maximum aggregate amount of director fees that can be paid to Non-Executive & Executive Directors is subject to approval by shareholders at the Annual General Meeting for the ensuing year.

Each Director receives a fee for being a Director of the Group. In addition, the Director's service agreements also has provisions to allow the Board, in its absolute discretion and as it considers appropriate, at any time during the Director's term in office, to grant or issue to the Director (or his nominee), options or shares:

- a) with or without vesting conditions;
- b) for such amount of cash consideration, which may be NIL cash consideration; and
- c) otherwise on such terms and conditions (including, where appropriate, exercise and expiry date).

The grant of share based payments to Directors is always subject to the Company obtaining any applicable regulatory and/or shareholder approvals, as required under the NSX Listing Rules and/or the *Corporations Act 2001*.

##### **B. Senior Management and Executive Director Remuneration**

The Group aims to reward Executives with a level and mix of remuneration commensurate with their position and responsibilities within the Group to:

- Reward Executives for the Group, business unit and individual performance against targets set by reference to appropriate benchmarks;
- Align the interests of Executives with those of shareholders;
- Link reward with the strategic goals and performance of the Group;
- Ensure total remuneration is competitive by market standards; and
- Executive remuneration is designed to support the Group's reward philosophies and to underpin the Group's growth strategy. The program comprises the following available components:
  - Fixed remuneration component; and
  - Variable remuneration component including cash bonuses paid, as well as options issued under the Employee Share Options Plan (ESOP).

## **Directors' Report**

### **For the Year Ended 30 June 2025**

#### **Remuneration report (audited) (continued)**

##### ***Fixed Remuneration***

Fixed remuneration, consisting of base salary, superannuation and non-monetary benefits, are reviewed annually by the CEO based on individual and business unit performance, the overall performance of the Group and comparable market remunerations.

##### ***Variable Remuneration***

The performance of KMP is measured against criteria agreed annually with each Executive. All bonuses and incentives must be linked to predetermined performance criteria. The policy is designed to attract the highest calibre of executives and reward them for performance results leading to long-term growth in shareholder wealth.

The objective of the Short-Term Incentive ("STI") program is to link the achievement of the Group's operational targets with the remuneration received by the executives charged with meeting those targets. The total potential STI available is set at a level to provide sufficient incentive to achieve the operational targets and such that the cost to the Group is reasonable.

Actual STI payments granted depend on the extent to which specific operating targets are met. The operational targets consist of a number of Key Performance Indicators (KPIs) covering both financial and non-financial measures of performance.

On an annual basis, the individual performance of each executive is rated and taken into account when determining the amount, if any, of the short-term incentive pool allocated to each executive. The aggregate of annual STI payments available for executives across the Group are usually delivered in the form of a cash bonus.

The long-term incentives ("LTI") include long service leave and share-based payments. Options are awarded to executives over a year of two to three years based on long-term incentive measures. These include market capitalisation measures, share price measures over a specific year, and achievement of continuous employment hurdle year of service. The Board has reviewed the long-term equity-linked performance incentives specifically for executives during the year ended 30 June 2025.

#### **Relationship between remuneration policy and Company performance**

The remuneration policy has been tailored to increase goal congruence between shareholders, directors and executives. The Group aims to align management remuneration to the strategic and business objectives and the creation of shareholder wealth. However, these are not necessarily consistent with the measures used in determining the variable amounts of remuneration to be awarded to KMPs. As a consequence, there may not always be a direct correlation between the statutory key performance measures and the variable remuneration awarded.

The following table summarises the earnings of the Group for the financial year ended 30 June 2025 and the factors that are considered to affect total shareholders return ("TSR"):

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
Total revenue/income	<b>62,760</b>	<b>36,984</b>
Net profit/(loss) after income tax	<b>(1,028,531)</b>	<b>(296,768)</b>
Share price at financial year end	<b>0.38</b>	<b>-</b>
Basic earnings per share (cents per share)	<b>(0.63)</b>	<b>(0.23)</b>
Dividends declared (cents per share)	<b>-</b>	<b>-</b>

## **Directors' Report**

### **For the Year Ended 30 June 2025**

#### **Remuneration report (audited) (continued)**

##### **Details of remuneration**

Details of the remuneration of key management personnel are set out in the tables in the following pages.

##### *Voting and comments made at the company's 2024 Annual General Meeting ('AGM')*

At the 2024 AGM, 100% of the votes received supported the adoption of the remuneration report for the year ended 30 June 2024. The company did not receive any specific feedback at the AGM regarding its remuneration practices.

##### **Key Management Personnel - Directors and Executives**

The key management personnel ("KMP") of the Group consisted of the following Directors and executives during the year:

<b>Executive Directors</b>	<b>Position</b>
Dr Kah Meng Lim	Group Managing Director and Chief Executive Officer (CEO)
<b>Non-Executive Directors</b>	<b>Position</b>
Mr Sah Soon Lim	Independent / Non-Executive Director
Mr William Bass (Appointed 1 October 2024)	Independent / Non-Executive Director
Mr Cody Blackhurst (Appointed 1 October 2024)	Independent / Non-Executive Director
Mr Matthew Leonard (Resigned 8 October 2024)	Independent / Non-Executive Director
Mr Justyn Stedwell (Resigned 8 October 2024)	Independent / Non-Executive Director
<b>Other KMP</b>	<b>Position</b>
Mr Danny Hock Kiong Heng (Resigned 4 October 2024)	Chief Financial Officer (CFO)
Dr Ron Eng Lee Tan (Resigned 31 October 2024)	Chief Scientific Officer (CSO)

##### **Key Management Personnel - Employee and Service Agreements**

The Company has entered into Director's Service Agreements with each of the Directors of the Company whereby the upper limit of the remuneration payable by the Company under such agreements to each Director is as follows:

- Dr Kah Meng Lim (Group Managing Director) – \$14,800 per annum
- Mr Sah Soon Lim (Executive Director) – \$35,000 per annum
- Mr Cody Blackhurst (Independent / Non-Executive Director) – \$40,000 per annum
- Mr William Bass (Independent / Non-Executive Director) – \$45,000 per annum.

Further, the following persons are employed by the Group under executive employment agreements, as follows:

- Dr Kah Meng Lim (Chief Executive Officer) receives an annual salary of S\$120,000 plus a transport allowance of S\$24,000 per annum (commencing from 1 March 2024). Other key terms include:
  - Either party may terminate the agreement without cause on 3 months' notice to the other party;
  - The Group will provide hospital and insurance cover for the employee and his immediate family.

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Report For the Year Ended 30 June 2025

#### Remuneration report (audited) (continued)

#### Details of remuneration (continued)

#### Remuneration details for the year ended 30 June 2025

The following table of benefits and payment details, in respect to the financial year, the components of remuneration for each member of the key management personnel of the Group.

#### Table of benefits and payments

	Short Term Employee Benefits		Post-Employment Benefits			
	Salary & fees		Superannuation Contributions			
	\$	\$	\$	\$	Total \$	Total \$
	2025	2024	2025	2024	2025	2024
<b>Directors</b>						
<b>Executive Director</b>						
Dr Kah Meng Lim	183,264	38,083	-	-	183,264	38,083
<b>Non-Executive Directors</b>						
Mr Sah Soon Lim	29,800	5,550	-	-	29,800	5,550
Mr Cody Blackhurst *	30,000	-	-	-	30,000	-
Mr William Bass *	34,000	-	-	-	34,000	-
Mr Justyn Stedwell	10,000	11,250	-	-	10,000	11,250
Mr Matthew Leonard	10,000	11,250	-	-	10,000	11,250
<b>Other KMP</b>						
Mr Danny Hock Kiong Heng (CFO)	47,759	33,815	-	-	47,759	33,815
Dr Ron Eng Lee Tan (CSO)	51,203	47,131	-	18,715	51,203	65,846
<b>Total</b>	<b>396,026</b>	<b>147,079</b>	<b>-</b>	<b>18,715</b>	<b>396,026</b>	<b>165,794</b>

\* only include the fees earned in their capacity of KMP and excludes fees paid to them in the other capacity

None of the remuneration paid to key management personnel for the year ended 30 June 2025 was performance related.

#### Cash performance-related bonuses

There were no cash bonuses granted as remuneration during the year that was paid or payable to key management personnel.

#### Share based compensation

No key management personnel were entitled to receive share-based compensation as part of their remuneration during the current financial year.

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Report

For the Year Ended 30 June 2025

Remuneration report (audited) (continued)

#### Key management personnel shareholdings

The number of ordinary shares in GO-Dx Corporation (Aust) Ltd held by each Key Management Personnel and their related parties up to and including the financial year is as follows:

30 June 2025	Balance at beginning of year	Acquisitions	Other changes during the year	Balance at end of year
<b>Directors</b>				
<b>Executive Directors</b>				
Dr Kah Meng Lim *	63,609,723	-	-	63,609,723
<b>Non-Executive Directors</b>				
Mr Sah Soon Lim	6,600,000	-	-	6,600,000
Mr Cody Blackhurst	-	-	-	-
Mr William Bass	-	-	-	-
Mr Justyn Stedwell **	500,000	-	(500,000)	-
Mr Matthew Leonard **	500,000	-	(500,000)	-
<b>Other KMP</b>				
Mr Danny Hock Kiong Heng (CFO) **	-	-	-	-
Dr Ron Eng Lee Tan (CSO) **	250,000	-	(250,000)	-
<b>Total</b>	<b>71,459,723</b>	<b>-</b>	<b>(1,250,000)</b>	<b>70,209,723</b>

\* Dr Kah Meng Lim holds 40,449,723 fully paid ordinary shares and his wife holds another 23,160,000 fully paid ordinary shares.

\*\* Departed during financial year

#### KMP related party transactions

The Group undertook the following transactions during the reporting year with:

- Key management personnel (KMP);
- A close member of the family of that person; or
- An entity over which the key management person or family member has, directly or indirectly, control, joint control or significant influence.

#### Transactions (excluding loans)

There were no transactions with KMP except as disclosed elsewhere in the remuneration report.

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Report For the Year Ended 30 June 2025

#### Remuneration report (audited) (continued)

#### Contracts with KMP related parties (continued)

#### Amounts due from/(to) KMP

The following information relates to outstanding KMP balances and other related movements during the reporting year on an aggregate basis.

	Balance at end of the year \$	Balance at the start of the year \$
Director: Dr Kah Meng Lim	-	156
<b>Companies related to Director, Dr Kah Meng Lim</b>		
Infiniclone Pte Ltd	3,597	3,334
Metagen Biologics Pte Ltd	1,449	1,339
Cell Differentiation Hub Pte Ltd	331	307
FEGO Biotech Pte Ltd	(3,157)	(2,927)
Cannioasis Pte Ltd	-	(2,802)
 Director: Mr Cody Blackhurst	-	-
Companies related to Director Mr Cody Blackhurst		
Caishen Holdings Pty Ltd	(17,600)	-
 Director: Mr William Bass	(8,250)	-
Companies related to Director Mr William Bass		
LAMAXA Pty Ltd	(9,916)	-

Amounts due to and from related parties are non-trade related, unsecured, interest-free, repayable upon demand and are to be settled in cash.

#### Contracts with Kah Meng Lim and his related parties

##### Supply and distribution agreements

The Company has been granted the worldwide exclusive right for the sale and purchase of the "G'Nest Deluxe" and "G'Nest Premium" products from FEGO Biotech Pte Ltd. The Company will be supplied the products at a cost of goods lower than the sale price to the Company's distributor and, in turn, earn profit on this margin. This agreement is considered to be on commercial and arms-length terms.

The Company has been granted the worldwide exclusive right for the sale and purchase of the "C'Neuros" product from NGF Bioenterprise Pte Ltd. The Company will be supplied the products at a cost of goods lower than the sale price to the Company's distributor and, in turn, earn profit on this margin. This agreement is considered to be on commercial and arms-length terms, and a related party transaction.

The Supply and Distribution Agreement with FEGO Biotech Pte Ltd commenced on 24 April 2023 for a ten (10) year term.

The Supply and Distribution Agreement with NGF Bioenterprise Pte Ltd commenced on 24 April 2023 for a ten (10) year term.



## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Directors' Report

For the Year Ended 30 June 2025

### Remuneration report (audited) (continued)

### Contracts with KMP related parties (continued)

#### GeneOasis licence agreement

The Company, via its wholly owned subsidiary, GO-Dx Corporation Ltd. ("GO-Dx Singapore"), has entered into a licence agreement with GeneOasis Bioscientific Pte. Ltd. ("GeneOasis") dated 5 January 2024. GeneOasis is a Singapore company that is controlled by the Company's Group Managing Director and Founder, Dr Kah Meng Lim.

Dr Kah Meng Lim is the inventor of the underlying intellectual property and has licenced the intellectual property rights to his controlled company, GeneOasis, to commercialise the intellectual property on his behalf. GeneOasis has, in turn, licenced the intellectual property to GO-Dx Singapore pursuant to the GeneOasis Licence Agreement. In order to protect GO-Dx Singapore from any risk that GeneOasis' licenced rights may be terminated, Dr Kah Meng Lim, GeneOasis and GO-Dx Singapore have entered into an agreement to confirm that Dr Kah Meng Lim will not exercise any termination rights in relation to his licence of intellectual property to GeneOasis without prior consent of GO-Dx Singapore.

The GeneOasis Licence Agreement provides for the exclusive worldwide grant of a licence to the Company to exploit, utilise and develop the intellectual property rights of the Immunological Extract Mining Platform, the Sialic Acid and Ganglioside Mining Platform, the Chemokine Mining Platform, the Polysaccharide Antigens Mining Platform, the Anthrocyanin Antigens Mining Platform and the Alkaloid Antigens Mining Platform. Under the terms of the GeneOasis Licence Agreement can use the intellectual property rights for the purposes of commercialisation (including exploiting the intellectual property in the Products and Services), and research and development activities, within the Field of diagnostics, health screening tests, health/bio-molecular mapping, healthcare, supplements, bio data mining and health artificial intelligence (IP).

The key terms of the GeneOasis Licence Agreement are as follows:

- S\$300,000 as a one-time licence establishment fee payable to GeneOasis.
- Up to S\$30,000 as a maintenance fee payable to GeneOasis for every 12 months in which GeneOasis incurs reasonable costs to maintain the IP.
- Three tranches of success fees are payable to GeneOasis, upon achievement of the following milestones:
  - Success fee 1 totalling S\$1,500,000 – payable upon the achievement of net sales revenue earned by the Company from the sale of the relevant products and services comprised in the IP totalling S\$10,000,000 within 5 years of the date of the licence agreement.
  - Success fee 2 totalling S\$750,000 – payable upon the achievement of net sales revenue earned by the Company from the sale of the relevant products and services comprised in the IP totalling S\$15,000,000 within 5 years of the date of the licence agreement.
  - Success fee 3 totalling S\$750,000 – payable upon the achievement of net sales revenue earned by the Company from the sale of the relevant products and services comprised in the IP totalling S\$20,000,000 within 5 years of the date of the licence agreement.
- 2% Royalty Fee – payable each half year calculated based on revenue earned by the Company from the sale of relevant products and services.
- The licence is on an exclusive basis, unless the exclusivity rights granted to the Company are revoked by GeneOasis due to the following exclusivity milestones not having been achieved by the Company:

## **GO-Dx Corporation (Aust) Ltd**

ACN 673 839 613

## **Directors' Report**

### **For the Year Ended 30 June 2025**

#### **Remuneration report (audited) (continued)**

#### **Contracts with KMP related parties (continued)**

- Exclusivity milestone 1 – Commercialisation of, or otherwise generation of revenue attributable to, at least 1 x new product or service utilising the IP within 24 months after the date of the licence agreement. No commercialisation or revenue generation has been achieved to the date of this Report.
- Exclusivity milestone 2 – Achievement of net sales revenue earned by the Company from the sale of the relevant products and provision of the relevant services totalling S\$500,000 within 24 months of the date of the licence agreement. Net sales revenue totalling S\$500,000 has not been achieved to the date of this Report .

GeneOasis may revoke the exclusivity rights granted to the Company by written notice only if the Company has been given a previous notice requiring it to achieve the relevant exclusivity milestone(s) within 6 months of that notice being served and has failed to do so.

If the exclusivity rights granted to GO-Dx are revoked, then the licence shall remain in effect on a non-exclusive basis (unless otherwise terminated in accordance with the terms of the GeneOasis Licence Agreement).

The licence granted by GeneOasis commenced on 31 August 2023 and the term of the licence granted by GeneOasis to GO-Dx shall continue in perpetuity (unless terminated in accordance with the terms of the GeneOasis Licence Agreement).

#### **Contract with Cody Blackhurst related party**

Caishen Holdings Pty Ltd provides company secretarial, NSX lodgement & technical advice for an annual fee of \$26,400, plus GST on commercial and arm's length terms.

- Agreement may be terminated with 30 days written notice
- Caishen agrees to provide transition support for further 90 days at the Service Rate.

The Company was charged \$18,000 during the year.

#### **Contract with William Bass related party**

LAMAXA Pty Ltd provides ASIC, Corporations Law, NSX, accounting & technical advice for an annual fee of \$44,000, plus GST on commercial and arm's length terms.

- Agreement may be terminated with 30 days written notice
- LAMAXA agrees to provide transition support for further 90 days at the Service Rate.

The Company was charged \$30,000 during the year.


#### **End of Audited Remuneration Report**

**GO-Dx Corporation (Aust) Ltd**

ACN 673 839 613

**Directors' Report**  
**For the Year Ended 30 June 2025**

This director's report, incorporating the remuneration report, is signed in accordance with a resolution of the Board of Directors.



.....

Dated 2 October 2025

**Auditor's independence declaration**

As lead auditor for the audit of the consolidated financial report of GO-Dx Corporation (Aust) Ltd ("the Company") and its controlled entities ("the Group") for the year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (a) the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- (b) any applicable code of professional conduct in relation to the audit.

This declaration is in relation to the GO-Dx Corporation (Aust) Ltd and the entities it controlled during the year.



**HLB Mann Judd**  
**Chartered Accountants**

Melbourne  
2 October 2025



**Jude Lau**  
**Partner**

## Consolidated Statement of Profit or Loss and Other Comprehensive Income

For the Year Ended 30 June 2025

		22 December 2023 -	
		30 June 2025	30 June 2024
	Note	\$	\$
Revenue from sale of goods		15,231	-
Other income	3	47,529	36,984
Cost of sales		(14,804)	-
Consulting and professional fees		(332,653)	(219,405)
Depreciation expense	4	(2,239)	(899)
Employee benefits expense (including directors' fees)	4	(377,613)	(92,558)
Finance expenses	4	(887)	(570)
Occupancy expenses	4	(26,673)	(5,634)
Office and administration costs		(336,422)	(14,686)
<b>Loss before income tax</b>		<b>(1,028,531)</b>	<b>(296,768)</b>
Income tax expense	5	-	-
<b>Net loss for the year</b>		<b>(1,028,531)</b>	<b>(296,768)</b>
<b>Other comprehensive income/(loss), net of income tax</b>			
<b>Items that will not be reclassified subsequently to profit or loss</b>		-	-
<b>Items that will be reclassified to profit or loss when specific conditions are met</b>			
Exchange differences on translating foreign controlled entities	15	13,660	(51,003)
<b>Other comprehensive income/(loss) for the year, net of tax</b>		<b>13,660</b>	<b>(51,003)</b>
<b>Total comprehensive loss for the year</b>		<b>(1,014,871)</b>	<b>(347,771)</b>
Loss attributable to:			
Members of the parent entity		(1,028,531)	(296,768)
Total comprehensive loss attributable to:			
Members of the parent entity		(1,014,871)	(347,771)
<b>Earnings per share:</b>			
Basic earnings/(loss) per share (cents)	18	(0.63)	(0.23)
Diluted earnings/(loss) per share (cents)	18	(0.63)	(0.23)

# GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Consolidated Statement of Financial Position As At 30 June 2025

		30 June 2025	30 June 2024
	Note	\$	\$
<b>ASSETS</b>			
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	8	330,489	673,557
Trade and other receivables	9	5,472	5,229
Inventories	10	16,617	-
Other assets	11	-	442,886
<b>TOTAL CURRENT ASSETS</b>		<b>352,578</b>	<b>1,121,672</b>
<b>NON-CURRENT ASSETS</b>			
Property, plant and equipment	12	2,172	4,141
<b>TOTAL NON-CURRENT ASSETS</b>		<b>2,172</b>	<b>4,141</b>
<b>TOTAL ASSETS</b>		<b>354,750</b>	<b>1,125,813</b>
<b>LIABILITIES</b>			
<b>CURRENT LIABILITIES</b>			
Trade and other payables	13	317,357	308,475
<b>TOTAL CURRENT LIABILITIES</b>		<b>317,357</b>	<b>308,475</b>
<b>TOTAL LIABILITIES</b>		<b>317,357</b>	<b>308,475</b>
<b>NET ASSETS</b>		<b>37,393</b>	<b>817,338</b>
<b>EQUITY</b>			
Issued capital	14	1,415,631	1,180,705
Reserves	15	(53,035)	(66,695)
Accumulated losses	16	(1,325,299)	(296,768)
Non-controlling interest		96	96
<b>TOTAL EQUITY</b>		<b>37,393</b>	<b>817,338</b>

The accompanying notes form part of these financial statements.

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Consolidated Statement of Changes in Equity For the Year Ended 30 June 2025

	Ordinary Shares	Accumulated Losses	Foreign Currency Translation Reserve	Common Control Reserve	Non-Controlling Interests	Total	
Note	\$	\$	\$	\$	\$	\$	
Balance at 22 December 2023	-	-	-	-	-	-	
Loss for the period to 30 June 2025	16	(296,768)	-	-	-	(296,768)	
Total other comprehensive income for the period	15	-	(51,003)	-	-	(51,003)	
Transactions with owners in their capacity as owners							
Contribution of equity, net of transaction costs	14	2	-	-	-	2	
Common control transaction	15	1,180,703	(15,692)	-	96	1,165,107	
Balance at 30 June 2024		1,180,705	(296,768)	(66,695)	-	96	817,338
Loss for the year to 30 June 2025	16	-	(1,028,531)	-	-	-	(1,028,531)
Total other comprehensive income for the year	15	-	-	13,660	-	-	13,660
Transactions with owners in their capacity as owners							
Contribution of equity, net of transaction costs	14	234,926	-	-	-	-	234,926
Balance at 30 June 2025		1,415,631	(1,325,299)	(53,035)	-	96	37,393

The accompanying notes form part of these financial statements.

# GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

## Consolidated Statement of Cash Flows For the Year Ended 30 June 2025

		22 December 2023 - 30 June 2024
Note	30 June 2025 \$	30 June 2024 \$
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Receipts from customers and other receipts	28,507	-
Payments to suppliers and employees	(857,860)	(156,113)
Finance costs paid	(887)	-
Interest received	-	2,747
<b>Net cash provided by/(used in) operating activities</b>	<b>17 (830,240)</b>	<b>(153,366)</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Cash acquired via common control transaction	-	1,052,543
Payment for additional investments	(58,919)	(8,336)
<b>Net cash provided by/(used in) investing activities</b>	<b>(58,919)</b>	<b>1,044,207</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Proceeds from issue of shares, net of costs	498,206	-
Payment of IPO related expenses	-	(166,484)
<b>Net cash provided by/(used in) financing activities</b>	<b>498,206</b>	<b>(166,484)</b>
Effects of exchange rate changes on cash and cash equivalents	47,885	(50,800)
Net increase/(decrease) in cash and cash equivalents held	(390,953)	673,557
Cash and cash equivalents at beginning of year	673,557	-
<b>Cash and cash equivalents at end of the year</b>	<b>8(a) 330,489</b>	<b>673,557</b>

The accompanying notes form part of these financial statements.



## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

The consolidated financial report covers GO-Dx Corporation (Aust) Ltd ("the Company") and its controlled entities ('the Group'). GO-Dx Corporation (Aust) Ltd is a for-profit listed public company limited by shares, incorporated and domiciled in Australia.

Each of the entities within the Group prepare their financial statements based on the currency of the primary economic environment in which the entity operates (functional currency). The consolidated financial statements are presented in Australian dollars which is the parent entity's functional and presentation currency.

The financial report was authorised for issue by the Directors on 2 October 2025.

The Company was incorporated on 22 December 2023 and listed on the National Stock Exchange on 15 July 2024. Its comparative information for FY 2024 covers the period 22 December 2023 to 30 June 2024.

#### **1 Material Accounting Policy Information**

##### **Basis of Preparation**

The financial statements are general purpose financial statements that have been prepared in accordance with the Australian Accounting Standards and the *Corporations Act 2001*. These financial statements comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

The financial statements, except for the cash flow information, have been prepared on an accruals basis and are based on historical costs modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

Material accounting policy information relating to the preparation of these financial statements are presented below.

##### **(a) Principle of consolidation**

The consolidated financial statements include the financial position and performance of controlled entities from the date on which control is obtained until the date that control is lost.

Intragroup assets, liabilities, equity, income, expenses and cashflows relating to transactions between entities in the consolidated entity have been eliminated in full for the purpose of these financial statements.

Appropriate adjustments have been made to a controlled entity's financial position, performance and cash flows where the accounting policies used by that entity were different from those adopted by the consolidated entity.

All controlled entities have the same financial year end as the parent.

A list of controlled entities is contained in Note 21 to the financial statements.

##### **Subsidiaries**

Subsidiaries are all entities (including structured entities) over which the parent has control. Control is established when the parent is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 1 Material Accounting Policy Information (continued)

##### (a) Principle of consolidation (continued)

###### *Common control transaction*

A business combination involving entities or businesses under common control is a business combination in which all of the combining entities or businesses are ultimately controlled by the same party or parties both before and after the business combination, and that control is not transitory. It is outside the scope of AASB 3 when the same group of individuals has, as a result of contractual arrangements, ultimate collective power to govern the financial and operating policies of each of the combining entities so as to obtain benefits from their activities, and that ultimate collective power is not transitory. Such transactions are accounted using the pre-combination carrying value without fair value uplift of the assets and liabilities transferred.

##### (b) Revenue and other income

###### **Revenue from contracts with customers**

Revenue is recognised on a basis that reflects the transfer of control of promised goods or services to customers at an amount that reflects the consideration the Group expects to receive in exchange for those goods or services.

Generally the timing of the payment for sale of goods and rendering of services corresponds closely to the timing of satisfaction of the performance obligations, however where there is a difference, it will result in the recognition of a receivable, contract asset or contract liability.

None of the revenue streams of the Group have any significant financing terms as there is less than 12 months between receipt of funds and satisfaction of performance obligations.

###### **Interest revenue**

Interest revenue is recognised using the effective interest method, which for floating rate financial assets is the rate inherent in the instrument.

##### (c) Income tax

The tax expense recognised in the consolidated statement of profit or loss and other comprehensive income comprises current income tax expense plus deferred tax expense.

Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (loss) for the year and is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the tax rates and laws that have been enacted or substantively enacted by the end of the reporting year. Current tax liabilities (assets) are measured at the amounts expected to be paid to (recovered from) the relevant taxation authority.

Deferred tax is provided on temporary differences which are determined by comparing the carrying amounts of tax bases of assets and liabilities to the carrying amounts in the consolidated financial statements.

Deferred tax is not provided for the following:

- The initial recognition of an asset or liability in a transaction that is not a business combination and at the time of the transaction, affects neither accounting profit nor taxable profit (tax loss).

## **Notes to the Financial Statements**

**For the Year Ended 30 June 2025**

### **1 Material Accounting Policy Information (continued)**

#### **(c) Income tax (continued)**

- Taxable temporary differences arising on the initial recognition of goodwill.
- Temporary differences related to investment in subsidiaries, associates and jointly controlled entities to the extent that the Group is able to control the timing of the reversal of the temporary differences and it is probable that they will not reverse in the foreseeable future.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting year.

Deferred tax assets are recognised for all deductible temporary differences and unused tax losses to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and losses can be utilised.

Current and deferred tax is recognised as income or an expense and included in profit or loss for the year except where the tax arises from a transaction which is recognised in other comprehensive income or equity, in which case the tax is recognised in other comprehensive income or equity respectively.

#### **(d) Goods and services tax (GST) and other similar taxes**

Revenue, expenses and assets are recognised net of the amount of goods and services tax (GST), except where the amount of GST incurred is not recoverable from the relevant taxation authorities.

Receivables and payables are stated inclusive of GST.

Cash flows in the consolidated statement of cash flows are included on a gross basis and the GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

#### **(e) Cash and cash equivalents**

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts.

Bank overdrafts are shown within short-term borrowings in current liabilities on the consolidated statement of financial position.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

#### **1 Material Accounting Policy Information (continued)**

##### **(f) Inventories**

Inventories are stated at the lower of cost and net realisable value. Costs incurred in bringing the inventories to their present location and condition are accounted for as follows:-

- trading goods – first in / first out

Where necessary, allowance is provided for damaged, obsolete and slow moving items to adjust the carrying value of inventories to the lower of cost and net realisable value.

The amount of any write-down of inventories to net realisable value and all losses of inventories shall be recognised as an expense in the period the write-down occurs.

When inventories are sold, the carrying amount of those inventories are recognised as an expense in the period in which the related revenue is recognised.

Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

##### **(g) Financial instruments**

Financial instruments are recognised initially on the date that the Group becomes party to the contractual provisions of the instrument.

On initial recognition, all financial instruments are measured at fair value plus transaction costs (except for instruments measured at fair value through profit or loss where transaction costs are expensed as incurred).

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 1 Material Accounting Policy Information (continued)

##### (g) Financial instruments (continued)

###### Financial assets

All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.

###### *Classification*

On initial recognition, the Group classifies its financial assets into the following category, those measured at:

- amortised cost.

###### *Amortised cost*

The Group's financial assets measured at amortised cost comprise trade and other receivables and cash and cash equivalents in the consolidated statement of financial position.

Subsequent to initial recognition, these assets are carried at amortised cost using the effective interest rate method less provision for impairment.

Interest income, foreign exchange gains or losses and impairment are recognised in profit or loss. Gain or loss on derecognition is recognised in profit or loss.

###### *Trade receivables and contract assets*

Impairment of trade receivables and contract assets have been determined using the simplified approach in AASB 9 which uses an estimation of lifetime expected credit losses.

The Group has determined the probability of non-payment of the receivable and contract asset and multiplied this by the amount of the expected loss arising from default.

The amount of the impairment is recorded in a separate allowance account with the loss being recognised in finance expense. Once the receivable is determined to be uncollectable then the gross carrying amount is written off against the associated allowance.

Where the Group renegotiates the terms of trade receivables due from certain customers, the new expected cash flows are discounted at the original effective interest rate and any resulting difference to the carrying value is recognised in profit or loss.

###### *Other financial assets measured at amortised cost*

Impairment of other financial assets measured at amortised cost are determined using the expected credit loss model in AASB 9. On initial recognition of the asset, an estimate of the expected credit losses for the next 12 months is recognised. Where the asset has experienced significant increase in credit risk then the lifetime losses are estimated and recognised.

## Notes to the Financial Statements

For the Year Ended 30 June 2025

### 1 Material Accounting Policy Information (continued)

#### (g) Financial instruments (continued)

##### Financial liabilities

The Group measures all financial liabilities initially at fair value less transaction costs, subsequently financial liabilities are measured at amortised cost using the effective interest rate method.

The financial liabilities of the Group comprise trade payables.

#### (h) Trade and other receivables

Trade and other receivables include amounts due from customers for goods sold and services performed in the ordinary course of business. Receivables expected to be collected within 12 months of the end of the reporting year are classified as current assets. All other receivables are classified as non-current assets.

#### (i) Property, plant and equipment

Each class of property, plant and equipment is carried at cost less, where applicable, any accumulated depreciation and impairment.

##### Depreciation

Property, plant and equipment, excluding freehold land, is depreciated on a straight-line basis over the asset's useful life to the Group, commencing when the asset is ready for use.

The estimated useful lives used for each class of depreciable asset are shown below:

Fixed asset class	Useful life
Computer Equipment	3 years

At the end of each annual reporting year, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate.

#### (j) Impairment of non-financial assets

At the end of each reporting year the Group assesses whether there is any indication that an asset may be impaired. The assessment will include considering external sources of information and internal sources of information. If such an indication exists, an impairment test is carried out on the asset by comparing the recoverable amount of the asset, being the higher of the asset's fair value less costs of disposal and value in use to the asset's carrying amount. Any excess of the asset's carrying amount over its recoverable amount is recognised immediately in profit or loss, unless the asset is carried at a revalued amount in accordance with another AAS (e.g. in accordance with the revaluation model in AASB 116 *Property, Plant and Equipment*). Any impairment loss of a revalued asset is treated as a revaluation decrease in accordance with that other AAS.

Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Impairment testing is performed annually for goodwill and intangible assets with indefinite lives.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

#### **1 Material Accounting Policy Information (continued)**

##### **(k) Trade and other payables**

Trade and other payables represent the liabilities for goods and services received by the Group that remain unpaid at the end of the reporting year. Due to their short-term nature, they are measured at amortised cost and are not discounted. The balance is recognised as a current liability with the amounts normally paid within 30 days of recognition of the liability.

##### **(l) Employee benefits**

###### **Short-term employee benefits**

Provision is made for the Group's obligation for short-term employee benefits. Short-term employee benefits are benefits (other than termination benefits) that are expected to be settled wholly before 12 months after the end of the annual reporting year in which the employees render the related service, including wages and salaries. Short-term employee benefits are measured at the (undiscounted) amounts expected to be paid when the obligation is settled.

The Group's obligations for short-term employee benefits such as wages and salaries are recognised as a part of current trade and other payables in the consolidated statement of financial position.

###### **Other long-term employee benefits**

Provision is made for employees' long service leave and annual leave entitlements not expected to be settled wholly within 12 months after the end of the annual reporting year in which the employees render the related service. Other long-term employee benefits are measured at the present value of the expected future payments to be made to employees. Expected future payments incorporate anticipated future wage and salary levels, durations of service and employee departures and are discounted at rates determined by reference to market yields at the end of the reporting year on government bonds that have maturity dates that approximate the terms of the obligations. Upon the re-measurement of obligations for other long-term employee benefits, the net change in the obligation is recognised in profit or loss as a part of employee benefits expense.

The Group's obligations for long-term employee benefits are presented as non-current provisions in its statement of financial position, except where the Group does not have an unconditional right to defer settlement for at least 12 months after the end of the reporting year, in which case the obligations are presented as current provisions.

##### **(m) Share capital**

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares and share options which vest immediately are recognised as a deduction from equity, net of any tax effects.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

#### **1 Material Accounting Policy Information (continued)**

##### **(n) Foreign currency transactions and balances**

###### **Transaction and balances**

Foreign currency transactions are recorded at the spot rate on the date of the transaction.

At the end of the reporting year:

- Foreign currency monetary items are translated using the closing rate;
- Non-monetary items that are measured at historical cost are translated using the exchange rate at the date of the transaction; and
- Non-monetary items that are measured at fair value are translated using the rate at the date when fair value was determined.

Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition or in prior reporting years are recognised through profit or loss, except where they relate to an item of other comprehensive income or whether they are deferred in equity as qualifying hedges.

###### **Group companies**

The financial results and position of foreign operations whose functional currency is different from the Group's presentation currency are translated as follows:

- assets and liabilities are translated at year-end exchange rates prevailing at that reporting date;
- income and expenses are translated at average exchange rates for the year where the average rate approximates the rate at the date of the transaction; and
- retained earnings are translated at the exchange rates prevailing at the date of the transaction.

Exchange differences arising on translation of foreign operations are transferred directly to the Group's foreign currency translation reserve in the consolidated statement of financial position. These differences are recognised in the consolidated statement of profit or loss and other comprehensive income in the year in which the operation is disposed.

##### **(o) Earnings per share**

Basic earnings per share is calculated by dividing the profit attributable to owners of the company by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share adjusts the basic earnings per share to take into account the after-tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.



## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

#### **1 Material Accounting Policy Information (continued)**

##### **(p) Going concern**

During the financial year ended 30 June 2025, the Group had cash outflows from operating activities of \$830,240, and incurred a net loss from operating activities of \$1,028,531. Notwithstanding these factors, the financial statements for the year ended 30 June 2025 have been prepared on the basis that the Group is a going concern and therefore, contemplates the continuity of normal business activity, realisation of assets and settlement of liabilities in the normal course of business.

The Directors having prepared a cash flow forecast covering a period of 12 months, from the signing date and having considered the following factors, and concluded that the Group is a going concern:

- On 30 September 2025, the Company entered into a convertible note agreement with a related party, which provides the Group with a facility of \$500,000, sufficient to cover expected the outflows over the next 12 months from the signing date of these accounts;
- The company can explore effecting a fund raise;
- The Directors are confident they can manage discretionary spending and suspend/amend the amounts payable to directors to ensure that the cash reserve is conserve and available to meet the Group's debts as and when they fall due.

As a result, the financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activity, realisation of assets and settlement of liabilities in the normal course of business for the following reasons.

Notwithstanding this, there exists a material uncertainty that may cast doubt on the Group's ability to continue as a going concern and, therefore, that it may be unable to realise its assets and discharge its liabilities in the normal course of business. Accordingly, the financial report does not include any adjustments relating to the recoverability or classification of recorded asset amounts, nor the amounts or classification of liabilities that might be necessary should the Group not be able to continue as a going concern.

## Notes to the Financial Statements

For the Year Ended 30 June 2025

### 1 Material Accounting Policy Information (continued)

#### (q) New Accounting Standards and Interpretations not yet mandatory or early adopted

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the consolidated entity for the annual reporting period ended 30 June 2025. The consolidated entity's assessment of the impact of these new or amended Accounting Standards and Interpretations, most relevant to the consolidated entity, are set out below.

##### *AASB 18 Presentation and Disclosure in Financial Statements*

This standard is applicable to annual reporting periods beginning on or after 1 January 2027 and early adoption is permitted. The standard replaces IAS 1 'Presentation of Financial Statements', with many of the original disclosure requirements retained and there will be no impact on the recognition and measurement of items in the financial statements. But the standard will affect presentation and disclosure in the financial statements, including introducing five categories in the statement of profit or loss and other comprehensive income: operating, investing, financing, income taxes and discontinued operations. The standard introduces two mandatory sub-totals in the statement: 'Operating profit' and 'Profit before financing and income taxes'. There are also new disclosure requirements for 'management-defined performance measures', such as earnings before interest, taxes, depreciation and amortisation ('EBITDA') or 'adjusted profit'. The standard provides enhanced guidance on grouping of information (aggregation and disaggregation), including whether to present this information in the primary financial statements or in the notes. The consolidated entity will adopt this standard from 1 July 2027 and it is expected that there will be a significant change to the layout of the statement of profit or loss and other comprehensive income.

### 2 Critical Accounting Judgements, Estimates and Assumptions

The directors make estimates and judgements during the preparation of these consolidated financial statements regarding assumptions about current and future events affecting transactions and balances.

These estimates and judgements are based on the best information available at the time of preparing the financial statements, however as additional information is known then the actual results may differ from the estimates.

The directors have not made any significant accounting estimates or judgements which are likely to affect the future results of the Company.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 3 Other Income

	30 June 2025	22 December 2023 - 30 June 2024
	\$	\$
Interest income	614	2,747
Foreign currency gain on financial assets and liabilities	34,225	31,206
Other	12,690	3,031
	<b>47,529</b>	<b>36,984</b>

#### 4 Expenses

The result for the year includes the following specific expenses:

	30 June 2025	22 December 2023 - 30 June 2024
	\$	\$
Cost of sales	14,804	-
Employee benefits expense (including directors' fees)	377,613	92,558
Depreciation expense - computer equipment	2,239	899
Rental expense on operating leases:		
- Minimum lease payments	26,673	5,634
Finance expenses: bank charges & interest	887	570
Write off of prepaid subscription – Pathomics Health	233,977	-

#### 5 Income Tax Expense

##### (a) Reconciliation of income tax to accounting profit:

	30 June 2025	22 December 2023 - 30 June 2024
	\$	\$
Loss before income tax	(1,028,531)	(296,768)
Statutory tax rate	30.00%	30.00%
Prima facie tax at the statutory rate	(308,559)	(89,030)
Tax effect of amounts which are not deductible/(taxable) in calculating taxable income:		
- non-deductible expenses	(1,522)	270
Non-deductible		
- non-taxable unrealised translation gain	(4,087)	(9,303)
- difference in tax rates	91,604	-
- tax losses not brought to account	222,564	98,063
<b>Income tax expense</b>	<b>-</b>	<b>-</b>

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 5 Income Tax Expense (continued)

##### (b) Tax losses not recognised

	2025	2024
	\$	\$
Unused tax losses for which no deferred tax asset has been recognised	1,068,757	326,877
Potential tax benefit at 30%	320,627	98,063

The above potential tax benefit for tax losses has not been recognised in the consolidated statement of financial position. These tax losses can only be utilised in the future if the continuity of ownership test is passed, or failing that, the same business test is passed.

#### 6 Acquisition of a Subsidiary - Common Control Transaction

On 2 February 2024, the parent Company acquired a 100% interest of GO-Dx Corporation Ltd. (a company incorporated in Singapore) and resulted in GO-Dx Corporation (Aust) Ltd obtaining control of GO-Dx Corporation Ltd.

In determining the accounting treatment to be applied to this acquisition, the Directors gave consideration to the fact that the Company and GO-Dx Corporation Ltd. were controlled by the same group of major shareholders before and after the acquisition. Accordingly, it was determined that the acquisition met the definition of a re-organisation as outlined in AASB 3 Business Combination, whereby the variance between the purchase consideration paid and the net assets acquired is recognised in equity on consolidation.

The following table shows the assets acquired, liabilities assumed and the purchase consideration at the acquisition date.

	Acquiree's carrying amount \$ (2024)
<i>Purchase consideration:</i>	
- Fully paid ordinary shares	1,180,703
<b>Total purchase consideration</b>	<b>1,180,703</b>
<i>Assets or liabilities acquired:</i>	
Cash	1,052,543
Trade and other receivables	5,341
Plant and equipment	5,133
Other assets	172,954
Trade and other payables	(70,862)
<b>Total net identifiable assets</b>	<b>1,165,109</b>
Less: non-controlling interests	(98)
Less: Foreign exchange translation reserve	15,692
<b>Identifiable assets acquired and liabilities assumed</b>	<b>1,180,703</b>
Purchase consideration	1,180,703
Less: Identifiable assets acquired	(1,180,703)
<b>Excess of net assets over purchase consideration paid recognised as reserve</b>	<b>-</b>

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 7 Operating Segments

##### Segment information

##### Identification of reportable segments

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (Chief Operating Decision Maker) in assessing performance and determining the allocation of resources.

The Group operates in a single segment, being the medical diagnostics and diagnostics technology sectors of the healthcare industry, pioneering development and innovation with regard to personalised Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular, immunity, anti-ageing, neural health, and specific cancers. In respect of geographical segments, other than in Singapore, Australia is the Group's other geographical area.

##### Basis of accounting for purposes of reporting by operating segments

##### (a) Accounting policies adopted

Unless stated below, all amounts reported to the Board of Directors, being the Chief Operating Decision Maker with respect to operating segments, are determined in accordance with accounting policies that are consistent with those adopted in the annual financial statements of the Group.

##### (b) Segment assets

Where an asset is used across multiple segments, the asset is allocated to the segment that receives the majority of economic value from the asset. Usually, segment assets are clearly identifiable on the basis of their nature and physical location.

##### (c) Segment liabilities

Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

##### (d) Geographical information

In presenting information on the basis of geographical segments, segment revenue is based on the geographical location of customers whereas segment assets are based on the location of the assets.

	2025		2024	
	Sales to External Customers \$	Geographical Non-Current Assets \$	Sales to External Customers \$	Geographical Non-Current Assets \$
Australia	-	-	-	263,282
Singapore	15,231	2,172	-	862,531
	<b>15,231</b>	<b>2,172</b>	<b>-</b>	<b>1,125,813</b>

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 8 Cash and Cash Equivalents

	2025	2024
	\$	\$
Cash on hand	1,201	1,113
Cash at bank	329,288	672,444
<b>Total cash and cash equivalents</b>	<b>330,489</b>	<b>673,557</b>

##### (a) Reconciliation of cash

Cash and cash equivalents reported in the consolidated statement of cash flows are reconciled to the equivalent items in the consolidated statement of financial position as follows:  
Cash and cash equivalents

**Balance as per consolidated statement of cash flows**

<b>330,489</b>	<b>673,557</b>
<b>330,489</b>	<b>673,557</b>

#### 9 Trade and Other Receivables

	2025	2024
	\$	\$
<b>CURRENT</b>		
Amounts due from a KMP	-	156
Amounts due from related companies	5,372	4,980
Amount due from non-controlling interest	100	93
<b>Total current trade and other receivables</b>	<b>5,472</b>	<b>5,229</b>

Refer Note 22 for terms and conditions associated with related party balances

#### 10 Inventories

	2025	2024
	\$	\$
Consumable materials	16,617	-

#### 11 Other Assets

	2025	2024
	\$	\$
<b>CURRENT</b>		
Prepayments 11(a)	-	267,828
Deposits 11(b)	-	175,058
<b>Total current other assets</b>	<b>-</b>	<b>442,886</b>

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 11 Other Assets (continued)

##### (a) Prepayments

Prepaid IPO costs of \$263,280 to 30 June 2024 were transferred to issued capital on Company's NSX listing in July 2024.

##### (b) Deposit

The 2024 deposit relates to a prepaid share subscription in Pathomics Health Pte. Ltd for which the shares have not been allotted. Following a subsequent review during the year, the amount was written off in full.

#### 12 Property, Plant and Equipment

	2025 \$	2024 \$
<b>Computer equipment</b>		
At cost	6,884	6,382
Accumulated depreciation	(4,712)	(2,241)
<b>Total computer equipment</b>	<b>2,172</b>	<b>4,141</b>
<b>Total property, plant and equipment</b>	<b>2,172</b>	<b>4,141</b>

##### (a) Movements in carrying amounts of property, plant and equipment

Movement in the carrying amounts for each class of property, plant and equipment between the beginning and the end of the current and prior financial years:

	Computer Equipment \$	Total \$
<b>Period ended 30 June 2024</b>		
Balance at the beginning of year	-	-
Additions through common control transaction	5,133	5,133
<b>Depreciation expense</b>	<b>(899)</b>	<b>(899)</b>
<b>Foreign exchange movements</b>	<b>(93)</b>	<b>(93)</b>
<b>Balance at the end of the year</b>	<b>4,141</b>	<b>4,141</b>
<b>Year ended 30 June 2025</b>		
Balance at the beginning of year	4,141	4,141
Depreciation expense	(2,239)	(2,239)
Foreign exchange movements	270	270
<b>Balance at the end of the year</b>	<b>2,172</b>	<b>2,172</b>

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 13 Trade and Other Payables

	2025	2024
	\$	\$
<b>CURRENT</b>		
Trade payables	76,656	114,538
Sundry payables and accrued expenses	157,699	153,321
Accrued directors' fees	78,097	33,600
Amount due to related companies	3,157	5,729
Other payables	1,748	1,287
<b>Total current trade and other payables</b>	<b>317,357</b>	<b>308,475</b>

Trade and other payables are unsecured, non-interest bearing and are normally settled within 30 days. The carrying value of trade and other payables is considered a reasonable approximation of fair value due to the short-term nature of the balances. Refer to Note 22 for the terms and conditions associated with related party balances.

#### 14 Issued Capital

	2025	2024
	\$	\$
163,003,500 fully paid ordinary shares	1,415,631	1,180,705
<b>Total issued capital</b>	<b>1,415,631</b>	<b>1,180,705</b>

Details	Date	Shares	Issue price	\$
			\$	
Shares issued on incorporation of Company	22 Dec 2023	2	1	2
Issued as consideration for acquisition of GO-Dx	2 Feb 2024	161,649,998	0.0073	1,180,703
	<b>30 June 2024</b>	<b>161,650,000</b>		<b>1,180,705</b>
Shares issued on IPO	12 July 2024	1,353,500	0.38	514,330
Transaction cost		-		(279,404)
	<b>30 June 2025</b>	<b>163,003,500</b>		<b>1,415,631</b>

The holders of ordinary shares are entitled to participate in dividends and the proceeds on winding up of the Company. On a show of hands at meetings of the Company, each holder of ordinary shares has one vote in person or by proxy, and upon a poll each share is entitled to one vote.

The Company does not have authorised capital or par value in respect of its shares.

#### (a) Capital management

The key objectives of the Company when managing capital is to safeguard its ability to continue as a going concern and maintain optimal benefits to stakeholders. The Company defines capital as its equity and net debt.

There has been no change to capital risk management policies during the year.



## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 14 Issued Capital (continued)

##### (a) Capital management (continued)

The Company manages its capital structure and makes funding decisions based on the prevailing economic environment and has a number of tools available to manage capital risk. These include maintaining a diversified debt portfolio, the ability to adjust the size and timing of dividends paid to shareholders and the issue of new shares.

The Board monitors a range of financial metrics including return on capital employed and gearing ratios.

#### 15 Reserves

	2025	2024
	\$	\$
<b>Foreign currency translation reserve</b>		
Opening balance	(66,695)	-
Acquisition of GO-Dx Corporation Ltd.	-	(15,692)
Exchange differences on translating foreign controlled entities	13,660	(51,003)
<b>Closing balance</b>	<b>(53,035)</b>	<b>(66,695)</b>
<b>Total reserves</b>	<b>(53,035)</b>	<b>(66,695)</b>

##### (a) Foreign currency translation reserve

Exchange differences arising on translation of the foreign controlled entity are recognised in other comprehensive income - foreign currency translation reserve. The cumulative amount is reclassified to profit or loss when the net investment is disposed of.

#### 16 Accumulated Losses

	2025	2024
	\$	\$
Accumulated losses at the beginning of the financial year	(296,768)	-
Net loss for the year	(1,028,531)	(296,768)
<b>Accumulated losses at end of the financial year</b>	<b>(1,325,299)</b>	<b>(296,768)</b>

## Notes to the Financial Statements

For the Year Ended 30 June 2025

### 17 Cash Flow Information

#### Reconciliation of result for the year to cashflows from operating activities

	2025	2024
	\$	\$
Loss for the year	(1,028,531)	(296,768)
Non-cash flows in profit:		
- depreciation expense	2,239	899
- foreign exchange gain	(34,225)	-
- write off of prepaid subscriptions	233,977	-
Changes in assets and liabilities:		
- (increase)/decrease in debtors	(243)	-
- (increase)/decrease in other assets	4,548	1,684
- (increase)/decrease in inventory	(16,617)	-
- increase/(decrease) in trade and other payables	8,612	140,819
<b>Net cash provided by/(used in) operating activities</b>	<b>(830,240)</b>	<b>(153,366)</b>

### 18 Earnings Per Share

#### (a) Reconciliation of earnings to profit or loss from continuing operations

	2025	2024
	\$	\$
Net loss for the year attributable to the owners of the parent entity	(1,028,531)	(296,768)
Earnings used to calculate basic EPS from continuing operations	(1,028,531)	(296,768)
<b>Earnings used in the calculation of dilutive EPS from continuing operations</b>	<b>(1,028,531)</b>	<b>(296,768)</b>

#### (b) Earnings used to calculate overall earnings per share

Earnings used to calculate overall earnings per share	(1,028,531)	(296,768)
---	-------------	-----------

#### (c) Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS

	2025	2024
	No.	No.
Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS	162,962,710	126,289,063
<b>Weighted average number of ordinary shares outstanding during the year used in calculating dilutive EPS</b>	<b>162,962,710</b>	<b>126,289,063</b>
<b>Basic and diluted EPS</b>	<b>(0.63)</b>	<b>(0.23)</b>

## Notes to the Financial Statements

For the Year Ended 30 June 2025

### 19 Financial Risk Management

The Group's principal financial instruments comprise of trade receivable, trade payables, and cash at bank. The main purpose of holding these instruments is to invest surplus members' funds in order to maximise returns while not exposing the Group to high levels of risk.

This note presents information about the Group's exposure to financial instrument risks, its objectives, policies and processes for measuring and managing risk.

The totals for each category of financial instruments, measured in accordance with AASB 9 as detailed in the accounting policies to these financial statements, are as follows:

	Note	2025 \$	2024 \$
<b>Financial assets</b>			
<i>Held at amortised cost</i>			
Cash and cash equivalents	8	330,489	673,557
Trade and other receivables	9	5,472	5,229
<b>Total financial assets</b>		<b>335,961</b>	<b>678,786</b>
<b>Financial liabilities</b>			
<i>Financial liabilities measured at amortised cost</i>			
Trade and other payables	13	317,357	308,475
<b>Total financial liabilities</b>		<b>317,357</b>	<b>308,475</b>

#### Objectives, policies and processes

The Board of Directors has overall responsibility for the establishment and oversight of the Group's financial risk management framework. This includes the development of policies covering specific areas such as foreign exchange risk, interest rate risk, liquidity risk, and credit risk.

Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Group's activities.

The day-to-day risk management is carried out by the Group's finance function under policies and objectives which have been approved by the Board of Directors. Management has been delegated the authority for designing and implementing processes which follow the objectives and policies. This includes monitoring the levels of exposure to interest rate and foreign exchange rate risk and assessment of market forecasts for interest rate and foreign exchange movements.

The Board of Directors receives monthly reports which provide details of the effectiveness of the processes and policies in place.

It is, and has been throughout the year under review, the Group's policy that no trading of financial instruments shall be undertaken. The main risks arising from holding these financial instruments are foreign exchange risk, interest rate risk, liquidity risk and credit risk. The Group is not exposed to price risk. Mitigation strategies for specific risks faced are described below:

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 19 Financial Risk Management (continued)

##### Liquidity risk

Liquidity risk arises from the Group's management of working capital and the finance charges and principal repayments on its debt instruments. It is the risk that the Group will encounter difficulty in meeting its financial obligations as they fall due.

The Group's policy is to ensure that it will always have sufficient cash to allow it to meet its liabilities as and when they fall due. The Group maintains cash and marketable securities to meet its liquidity requirements for up to 30-day years.

Liquidity needs are monitored in various time bands, on a day-to-day and week-to-week basis, as well a rolling 30-day projection. Long-term liquidity needs for a 180-day and a 360-day year are identified monthly.

At the reporting date, these reports indicate that the Group expects to have sufficient liquid resources to meet its obligations under all reasonably expected circumstances.

The table below analyses the Group's financial liabilities into relevant maturity groupings based on their contractual maturities for all non-derivative financial liabilities. The amounts disclosed in the table are the contractual undiscounted cash flows. Balances due within 12 months equal their carrying balances as the impact of discounting is not significant.

The Group's liabilities have contractual maturities which are summarised below:

	Not later than 1 month	Less than 12 months	1 to 2 years	Total Contractual Cashflow/ Carrying Amount
	\$	\$	\$	\$
<b>2025</b>				
<b>Financial liabilities due for payment</b>				
Trade and other payables	317,357	-	-	317,357
<b>Total contractual outflows</b>	<b>317,357</b>	<b>-</b>	<b>-</b>	<b>317,357</b>
<b>2024</b>				
<b>Financial liabilities due for payment</b>				
Trade and other payables	308,475	-	-	308,475
<b>Total contractual outflows</b>	<b>308,475</b>	<b>-</b>	<b>-</b>	<b>308,475</b>

The timing of expected outflows is not expected to be materially different from contracted cashflows.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2025**

#### **19 Financial Risk Management (continued)**

##### **Liquidity risk (continued)**

##### **Credit risk**

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the Group.

Credit risk arises from cash and cash equivalents, and deposits with banks and financial institutions, as well as credit exposure from outstanding receivables.

The Group has adopted a policy of only dealing with creditworthy counterparties as a means of mitigating the risk of financial loss from defaults. The utilisation of credit limits by customers is regularly monitored by line management. Customers who subsequently fail to meet their credit terms are required to make purchases on a prepayment basis until creditworthiness can be re-established.

As a result of the nature of the Group's operations, the Group has minimal credit risk.

Management considers that all the financial assets that are not impaired for each of the reporting dates under review are of good credit quality, including those that are past due.

The credit risk for liquid funds and other short-term financial assets is considered negligible, since the counterparties are reputable banks with high quality external credit ratings.

The Group has no significant concentration of credit risk with respect to any single counterparty or group of counterparties.

The Group applies the AASB 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivables.

To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due. As at 30 June 2025 and 30 June 2024, the Group did not have any trade receivables, accordingly, expected credit losses were not assessed.

The Group does not hold any financial assets with terms that have been renegotiated, but which would otherwise be past due or impaired.

The other classes of receivables do not contain impaired assets.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 19 Financial Risk Management (continued)

##### Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices.

##### *(i) Interest rate risk*

The Group is exposed to interest rate risk as surplus funds are invested at floating rates.

The Group's policy is to minimise interest rate cash flow risk exposures on long-term financing. Longer-term borrowings, when used, are therefore usually at fixed rates. At the reporting date, the Group is exposed to changes in market interest rates through its bank deposits, which are subject to variable interest rates.

		2025	2024
	Note	\$	\$
<b>Floating rate instruments</b>			
Cash at bank	8	329,288	672,444
<b>Total floating rate instruments</b>		<b>329,288</b>	<b>672,444</b>

Should interest rates increase/decrease by 1%, the impact would be a \$3,292 increase/decrease to the Group's net assets position.

##### *(ii) Foreign exchange risk*

Exposure to foreign exchange risk may result in the fair value or future cash flows of a financial instrument fluctuating due to movement in foreign exchange rates of currencies in which the Group holds financial instruments which are other than the AUD functional currency of the Group.

Exposures to currency exchange rates arise from the Group's operations in Singapore, which are primarily denominated in Singapore Dollars (SGD). Further, the Group has two non-operating subsidiaries in Indonesia and the Philippines. Some exposures to currency exchange rates may also arise from these subsidiaries for which transactions are denominated in Indonesian Rupiah (IDR) and Philippine Peso (PHP), respectively.

The Group does not hedge nor apply hedge accounting. The implications of this decision are that unrealised foreign exchange gains and losses are recognised in profit and loss in the year in which they occur.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 19 Financial Risk Management (continued)

##### (ii) Foreign exchange risk (continued)

Foreign currency denominated financial assets and liabilities, translated into Australian Dollars at the closing rate, are as follows:

	SGD \$	IDR \$	PHP \$	Total \$
<b>2025</b>				
<i>Nominal amounts</i>				
Financial assets	149,888	94	1,350	151,332
Financial liabilities	(159,353)	-	(1,350)	(158,003)
<b>Short-term exposure</b>	<b>(9,465)</b>	<b>94</b>	<b>-</b>	<b>(6,671)</b>
<b>2024</b>				
<i>Nominal amounts</i>				
Financial assets	677,404	92	1,288	678,784
Financial liabilities	(106,228)	-	(1,287)	(107,515)
<b>Short-term exposure</b>	<b>571,176</b>	<b>92</b>	<b>1</b>	<b>571,269</b>

#### Net Fair Values

##### Fair value estimation

The fair values of financial assets and financial liabilities must be estimated for recognition and measurement or for disclosure purposes.

The carrying value less impairment provision of trade receivables and payables is a reasonable approximation of their fair values due to the short-term nature of trade receivables and payables. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Group for similar financial instruments. None of the Group's financial instruments are recognised at fair value post initial recognition.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 20 Key Management Personnel Remuneration

Any person(s) having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any Director (whether executive or otherwise) of that entity are considered key management personnel.

The names of Directors who have held office during the financial year are outlined in the Directors' Report.

##### *Other key management personnel*

The following persons are included as other former key management personnel:

Chief Financial Officer – Mr Danny Hock Kiong Heng (d)  
 Chief Scientific Officer – Dr Ron Eng Lee Tan (d)  
 (d) departed during the financial year

Refer to the remuneration report contained in the Directors' Report for details of the remuneration paid or payable to each member of the KMP for the year ended 30 June 2025.

Key management personnel compensation included within employee expenses for the year is shown below:

	2025	2024
		\$
Short-term employee benefits	396,026	147,079
Post-employment benefits	-	18,715
<b>Total key management personnel compensation</b>	<b>396,026</b>	<b>165,794</b>

#### 21 Interests in Subsidiaries

##### Composition of the Group

	Principal place of business / Country of Incorporation	Percentage Owned (%) <sup>*</sup> 2025	Percentage Owned (%) <sup>*</sup> 2024
<b>Subsidiaries:</b>			
GO-Dx Corporation Ltd.	Singapore	100.00	100.00
PT GoDx Corp Indonesia	Indonesia	99.99	99.99
Go-Dx Philippines Inc.	Philippines	99.99	99.99

\*The percentage of ownership interest held is equivalent to the percentage voting rights for all subsidiaries.

The Group has initiated the process to wind down Go-Dx Philippines Inc.(GDP).The unpaid share capital to GDP will not be made. As of the Report Date, the closure process is ongoing. The financial impact of the closure of GDP will be reflected in the Group's financial statements for the next financial year.



## **Notes to the Financial Statements**

**For the Year Ended 30 June 2024**

### **22 Related Parties**

**(a) The Group's main related parties are as follows:**

GO-Dx Corporation (Aust) Ltd is the parent entity.

Disclosures relating to key management personnel are set out in Note 20 and the remuneration report included in the Directors' report.

Interests in subsidiaries are set out in Note 21.

Other related parties include close family members of key management personnel and entities that are controlled or significantly influenced by those key management personnel or their close family members.

**(b) Transactions with related parties**

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

## Notes to the Financial Statements

For the Year Ended 30 June 2024

## 22 Related Parties (continued)

## (b) Transactions with related parties (continued)

The following transactions occurred with related parties:

	Purchases	Sales	Balance outstanding	
	\$	\$	Owed to the Company	Owed by the Company
	\$	\$	\$	\$
<b>2025</b>				
<b>KMP related parties</b>				
<b>Companies related to Director, Dr Kah Meng Lim</b>				
Infiniclone Pte Ltd	-	-	3,597	-
Metagen Biologics Pte Ltd	-	-	1,449	-
Cell Differentiation Hub Pte Ltd	-	-	331	-
FEGO Biotech Pte Ltd	-	-	-	3,157
<b>Mr Cody Blackhurst</b>				
Caishen Holdings Pty Ltd	19,800	-	-	6,600
<b>Mr William Bass</b>				
LAMAXA Pty Ltd	33,003	-	-	9,916
<b>2024</b>				
<b>KMP related parties</b>				
Director, Dr Kah Meng Lim	-	-	156	-
<b>Companies related to Director, Dr Kah Meng Lim</b>				
Infiniclone Pte Ltd	-	-	3,334	-
Metagen Biologics Pte Ltd	-	-	1,339	-
Cell Differentiation Hub Pte Ltd	-	-	307	-
FEGO Biotech Pte Ltd	-	-	-	2,927
Cannioasis Pte Ltd	-	-	-	2,802

Amounts due to and from related parties are non-trade related, unsecured, interest-free, repayable upon demand and are to be settled in cash.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2024**

#### **22 Related Parties (continued)**

##### **(c) Contracts with related parties**

###### **Supply and distribution agreements**

The Company has been granted the worldwide exclusive right for the sale and purchase of the “G’Nest Deluxe” and “G’Nest Premium” products from FEGO Biotech Pte Ltd. The Company will be supplied the products at a cost of goods lower than the sale price to the Company’s distributor and, in turn, earn profit on this margin. This agreement is considered to be on commercial and arms-length terms.

The Company has been granted the worldwide exclusive right for the sale and purchase of the “C’Neuros” product from NGF Bioenterprise Pte Ltd. The Company will be supplied the products at a cost of goods lower than the sale price to the Company’s distributor and, in turn, earn profit on this margin. This agreement is considered to be on commercial and arms-length terms, and a related party transaction.

The Supply and Distribution Agreement with FEGO Biotech Pte Ltd commenced on 24 April 2023 for a ten (10) year term.

The Supply and Distribution Agreement with NGF Bioenterprise Pte Ltd commenced on 24 April 2023 for a ten (10) year term.

###### **GeneOasis licence agreement**

The Company, via its wholly owned subsidiary, GO-Dx Corporation Ltd. (“GO-Dx Singapore”), has entered into a licence agreement with GeneOasis Bioscientific Pte. Ltd. (“GeneOasis”) dated 5 January 2024. GeneOasis is a Singapore company that is controlled by the Company’s Group Managing Director and Founder, Dr Kah Meng Lim.

Dr Kah Meng Lim is the inventor of the underlying intellectual property and has licenced the intellectual property rights to his controlled company, GeneOasis, to commercialise the intellectual property on his behalf. GeneOasis has, in turn, licenced the intellectual property to GO-Dx Singapore pursuant to the GeneOasis Licence Agreement. In order to protect GO-Dx Singapore from any risk that GeneOasis’ licenced rights may be terminated, Dr Kah Meng Lim, GeneOasis and GO-Dx Singapore have entered into an agreement to confirm that Dr Kah Meng Lim will not exercise any termination rights in relation to his licence of intellectual property to GeneOasis without prior consent of GO-Dx Singapore.

The GeneOasis Licence Agreement provides for the exclusive worldwide grant of a licence to the Company to exploit, utilise and develop the intellectual property rights of the Immunological Extract Mining Platform, the Sialic Acid and Ganglioside Mining Platform, the Chemokine Mining Platform, the Polysaccharide Antigens Mining Platform, the Anthrocyanin Antigens Mining Platform and the Alkaloid Antigens Mining Platform. Under the terms of the GeneOasis Licence Agreement can use the intellectual property rights for the purposes of commercialisation (including exploiting the intellectual property in the Products and Services), and research and development activities, within the Field of diagnostics, health screening tests, health/bio-molecular mapping, healthcare, supplements, bio data mining and health artificial intelligence (IP).

The key terms of the GeneOasis Licence Agreement are as follows:

- SGD300,000 as a one-time licence establishment fee payable to GeneOasis.
- Up to SGD30,000 as a maintenance fee payable to GeneOasis for every 12 months in which GeneOasis incurs reasonable costs to maintain the IP.

## **Notes to the Financial Statements**

### **For the Year Ended 30 June 2024**

#### **22 Related Parties (continued)**

##### **(c) Contracts with related parties (continued)**

###### **GeneOasis licence agreement (continued)**

- Three tranches of success fees are payable to GeneOasis, upon achievement of the following milestones:
  - Success fee 1 totalling SGD1,500,000 – payable upon the achievement of net sales revenue earned by the Company from the sale of the relevant products and services comprised in the IP totalling SGD10,000,000 within 5 years of the date of the licence agreement.
  - Success fee 2 totalling SGD750,000 – payable upon the achievement of net sales revenue earned by the Company from the sale of the relevant products and services comprised in the IP totalling SGD15,000,000 within 5 years of the date of the licence agreement.
  - Success fee 3 totalling SGD750,000 – payable upon the achievement of net sales revenue earned by the Company from the sale of the relevant products and services comprised in the IP totalling SGD20,000,000 within 5 years of the date of the licence agreement.
- 2% Royalty Fee – payable each half year calculated based on revenue earned by the Company from the sale of relevant products and services.
- The licence is on an exclusive basis, unless the exclusivity rights granted to the Company are revoked by GeneOasis due to the following exclusivity milestones not having been achieved by the Company:
  - Exclusivity milestone 1 – Commercialisation of, or otherwise generation of revenue attributable to, at least 1 x new product or service utilising the IP within 24 months after the date of the licence agreement. At the Report Date no new product or service utilising the IP has been achieved.
  - Exclusivity milestone 2 – Achievement of net sales revenue earned by the Company from the sale of the relevant products and provision of the relevant services totalling SGD\$500,000 within 24 months of the date of the licence agreement. At the Report Date net sales of SGD\$500,000 has not been achieved.

GeneOasis may revoke the exclusivity rights granted to the Company by written notice only if the Company has been given a previous notice requiring it to achieve the relevant exclusivity milestone(s) within 6 months of that notice being served and has failed to do so.

If the exclusivity rights granted to GO-Dx are revoked, then the licence shall remain in effect on a non-exclusive basis (unless otherwise terminated in accordance with the terms of the GeneOasis Licence Agreement).

- The licence granted by GeneOasis commenced on 31 August 2023 and the term of the licence granted by GeneOasis to GO-Dx shall continue in perpetuity (unless terminated in accordance with the terms of the GeneOasis Licence Agreement).

## Notes to the Financial Statements

For the Year Ended 30 June 2024

### 22 Related Parties (continued)

#### (c) Contracts with related parties (continued)

##### Company Secretarial Services Agreement

The Company has entered into an Agreement with Caishen Holdings Pty Ltd for the provision of secretarial services to the Company at the rate of \$26,400 (including GST) per annum. The Agreement may be terminated by either party with 30 days written notice.

##### Technical Support Agreement

The Company has entered into an Agreement with LAMAXA Pty Ltd for the provision of technical support services to the Company at the rate of \$44,000 (including GST) per annum. The Agreement may be terminated by either party with 30 days written notice.

### 23 Auditors' Remuneration

	30 June 2025 \$	22 December 2023 - 30 June 2024 \$
Remuneration of the auditor, HLB Mann Judd, for:		
- auditing or reviewing the financial statements	52,270	40,800
- preparation of investigating accountant's report for IPO	-	28,600
	<b>52,270</b>	<b>69,400</b>
Remuneration of other auditors of subsidiaries for:		
- auditing or reviewing the financial statements of subsidiaries	33,927	16,903
	<b>33,927</b>	<b>16,903</b>
<b>Total auditors' remuneration</b>	<b>86,197</b>	<b>86,303</b>

## **Notes to the Financial Statements**

**For the Year Ended 30 June 2025**

### **24 Capital and Operating Commitments**

#### **GeneOasis Licence Agreement**

Pursuant to the GeneOasis Licence Agreement an amount of up to S\$30,000 as a maintenance fee is payable to GeneOasis Bioscientific Pte. Ltd. ("GeneOasis") for every 12 months in which GeneOasis incurs reasonable costs to maintain the intellectual property. Refer to Note 22(c) for further details regarding this licence agreement.

### **25 Contingencies**

Pursuant to an executed licence agreement dated 5 January 2024, the Group has a contingent liability totalling S\$3,000,000 payable in respect of the success fees should the Group achieve certain net sales revenue milestones from the sale of the relevant products and services comprised in the Intellectual Property (IP) licensed from GeneOasis Bioscientific Pte Ltd (GeneOasis), a company incorporated in Singapore which is controlled by Dr Kah Meng Lim, who is a Director and CEO of the Company.

### **26 Events Occurring After the Reporting Date**

The consolidated financial report was authorised for issue on 2 October 2025 by the board of directors.

[a] Following review of operations, the directors commenced winding up of Go-Dx Philippines Inc., a company incorporated and domiciled in Philippines. This is incomplete at the reporting date.

[b] The Company entered into a Convertible Note Agreement with Dr KM Lim to support funding for the Group. The terms of the Convertible Note Agreement are :

Term : 1 year to Maturity Date 30 September 2026

Purpose: working capital support

Principal : A\$500,000

Interest: 2% simple per annum on drawn down funds

Conversion: A\$0.19 per share on principal sum & accrued interest at any time prior to Maturity Date

Except for the above, no other matters or circumstances have arisen since the end of the financial year which significantly affected or could significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 27 Parent Entity

The following information has been extracted from the books and records of the parent, GO-Dx Corporation (Aust) Ltd and has been prepared in accordance with Accounting Standards.

The financial information for the parent entity, GO-Dx Corporation (Aust) Ltd has been prepared on the same basis as the consolidated financial statements except as disclosed below.

#### *Investments in subsidiaries, associates and joint ventures*

Investments in subsidiaries, associates and joint venture entities are accounted for at cost in the consolidated financial statements of the parent entity. Dividends received from associates are recognised in the parent entity profit or loss, rather than being deducted from the carrying amount of these investments.

	2025 \$	2024 \$
<b>Statement of Financial Position</b>		
<b>Assets</b>		
Current assets	791	263,282
<b>Total Assets</b>	<b>791</b>	<b>263,282</b>
<b>Liabilities</b>		
Current liabilities	204,462	377,993
<b>Total Liabilities</b>	<b>204,462</b>	<b>377,993</b>
<b>Equity</b>		
Issued capital	1,415,631	1,180,705
Accumulated losses	(1,619,302)	(1,065,994)
<b>Total Equity (Net deficiency of assets)</b>	<b>(203,671)</b>	<b>(114,711)</b>
<b>Statement of Profit or Loss and Other Comprehensive Income</b>		
Total profit or loss for the year	(323,887)	(1,065,994)
Other comprehensive income	-	-
<b>Total comprehensive income</b>	<b>(323,887)</b>	<b>(1,065,994)</b>

#### **Guarantees**

The parent entity has not entered into a Deed of Cross-Guarantee with the effect that the Company guarantees debts in respect of its subsidiaries as at 30 June 2025 (2024: nil).

#### **Contingent liabilities**

The parent entity did not have any contingent liabilities as at 30 June 2025 (2024: nil).

#### **Contractual commitments**

The parent entity did not have any commitments as at 30 June 2025 (2024: nil).

## Notes to the Financial Statements

### For the Year Ended 30 June 2025

#### 28 Reconciliation of results reported in preliminary financial report to audited results

On 15 September 2025, the consolidated entity filed its Preliminary Final Report with the NSX. Subsequently, during the audit process, management identified a number of adjustments that impacted the results. Details are as follows:

	Preliminary Annual Report	30 June 2025 Adjustments	Final Annual Report
	\$	\$	\$
<b>Consolidated Statement of Profit or Loss and Other Comprehensive Income</b>			
Employee benefits expense (including directors' fees)	(308,314)	(69,299)	(377,613)
Finance expense	(2,239)	1,352	(887)
Office and administration costs	(335,227)	(1,195)	(336,422)
Loss before income tax	(959,252)	(69,279)	(1,028,531)
Exchange differences on translating foreign controlled entities	15,707	(2,047)	13,660
Other comprehensive income for the year	15,707	(2,047)	13,660
Total comprehensive loss for the period	(943,545)	(71,326)	(1,014,871)
<b>Consolidated Statement of Financial Position</b>			
Trade and other payables	246,031	71,326	317,357
Total current liabilities	246,031	71,326	317,357
Total liabilities	246,031	71,326	317,357
Net assets	108,719	(71,326)	37,393
Reserve	(50,988)	(2,047)	(53,035)
Accumulated losses	(1,256,020)	(69,279)	(1,325,299)
Total equity	108,719	(71,326)	37,393
<b>Consolidated Statement of Cash Flows</b>			
Receipts from customers and other receipts	45,770	(17,263)	28,507
Payments to suppliers and employees	(878,124)	20,264	(857,860)
Finance costs paid	-	(887)	(887)
Net cash provided by/(used in) operating activities	(832,354)	2,114	(830,240)
Payment for investments	(47,909)	(11,010)	(58,919)
Net cash provided by/(used in) investing activities	(47,909)	(11,010)	(58,919)
Proceeds from issue of shares, net of costs	514,330	(16,124)	498,206
Net cash provided by/(used in) financing activities	514,330	(16,124)	498,206
Effects of exchange rate changes on cash and cash equivalents	22,864	25,021	47,885



## **GO-Dx Corporation (Aust) Ltd**

ACN 673 839 613

## **Notes to the Financial Statements**

**For the Year Ended 30 June 2025**

### **29 Statutory Information**

The registered office and principal place of business of the Company is:

GO-Dx Corporation (Aust) Ltd

Level 15

Corporate Centre One

2 Corporate Court

BUNDALL, QUEENSLAND 4217

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Consolidated Entity Disclosure Statement As At 30 June 2025

#### Basis of preparation

This consolidated entity disclosure statement has been prepared in accordance with the s295(3A) of the *Corporations Act 2001* and includes the required information for GO-Dx Corporation (Aust) Ltd and the entities it controls in accordance with AASB 10 *Consolidated Financial Statements*.

#### Tax residency

S295(3A)(vi) of the *Corporations Act 2001* defines tax residency as having the meaning in the *Income Tax Assessment Act 1997*. The determination of tax residency may involve judgement as there are different interpretations that could be adopted, and which could give rise to different conclusions regarding residency.

In determining tax residency, the consolidated entity has applied the following interpretations:

##### *Australian tax residency*

Current legislation and judicial precedent has been applied, including having regard to the Tax Commissioner's public guidance.

##### *Foreign tax residency*

Where appropriate, independent tax advisers have been engaged to assist in the determination of tax residency to ensure applicable foreign tax legislation has been complied with.

Entity Name	Entity Type	Country of Incorporation	% of Share Capital	Australian or Foreign Tax Resident
GO-Dx Corporation (Aust) Ltd	Body Corporate	Australia	N/A	Australian
GO-Dx Corporation Ltd.	Body Corporate	Singapore	100%	Foreign - Singapore
PT GoDx Corp Indonesia	Body Corporate	Indonesia	99.99%	Foreign - Singapore
Go-Dx Philippines Inc.	Body Corporate	Philippines	99.99%	Foreign - Singapore

## GO-Dx Corporation (Aust) Ltd

ACN 673 839 613

### Directors' Declaration


In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, the Accounting Standards, the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes comply with International Financial Reporting Standards as issued by the International Accounting Standards Board as described in note 1 to the financial statements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2025 and of its performance for the financial year ended on that date;
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable based on the factors outlined in note 1(p) of the financial statements;
- the information disclosed in the attached consolidated entity disclosure statement is true and correct.

The directors have been given the declarations required by section 295A of the Corporations Act 2001.

Signed in accordance with a resolution of directors made pursuant to section 295(5)(a) of the Corporations Act 2001.

On behalf of the directors



Director

Dated 2 October 2025

## Independent Auditor's Report to the Members of GO-Dx Corporation (Aust) Ltd

### REPORT ON THE AUDIT OF THE FINANCIAL REPORT

#### Opinion

We have audited the financial report of GO-Dx Corporation (Aust) Ltd ("the Company") and its controlled entities ("the Group"), which comprises the consolidated statement of financial position as at 30 June 2025, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated cashflow statement for the year then ended, and notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the *Corporations Act 2001*, including:

- (a) giving a true and fair view of the Group's financial position as at 30 June 2025 and of its financial performance for the year then ended; and
- (b) complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

#### Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* ("the Code") that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Material Uncertainty Regarding Going Concern

We draw attention to Note 1(p) *Going concern* in the financial report, which indicates that the Group had cash outflows from operating activities of \$830,240 and incurred a net loss of \$1,028,531 during the year ended 30 June 2025. These events or conditions, along with other matters as set forth in Note 1(p) *Going concern*, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our opinion is not modified in respect of this matter.

#### Key Audit Matters

Except for the matter described in the *Material Uncertainty Regarding Going Concern* section, we have determined that there are no other key audit matters to communicate in our report.

[hlb.com.au](http://hlb.com.au)

**HLB Mann Judd (VIC) Partnership ABN 20 696 861 713**

Level 9, 550 Bourke Street, Melbourne VIC 3000 | GPO Box 2850, Melbourne VIC 3001

T: +61 (0) 3 9606 3888 F: +61 (0) 3 9606 3800 E: [mailbox@hlbvic.com.au](mailto:mailbox@hlbvic.com.au)

Liability limited by a scheme approved under Professional Standards Legislation.

HLB Mann Judd (VIC) Partnership is a member of HLB International, the global advisory and accounting network

### **Information Other than the Financial Report and Auditor's Report Thereon**

The directors are responsible for the other information. The other information comprises the information included in the Group's annual report for the year ended 30 June 2025, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of the Directors for the Financial Report**

The directors of the Company are responsible for the preparation of:

- (a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001*; and
- (b) the consolidated entity disclosure statement that is true and correct in accordance with the *Corporations Act 2001*, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

### **Auditor's Responsibilities for the Audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the financial report. We are responsible for the direction, supervision and performance of the Group audit. We remain solely responsible for our audit opinion.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## **REPORT ON THE REMUNERATION REPORT**

### **Opinion on the Remuneration Report**

We have audited the Remuneration Report included in pages 8 to 16 of the annual report for the year ended 30 June 2025.

In our opinion, the Remuneration Report of the Group for the year ended 30 June 2025 complies with section 300A of the *Corporations Act 2001*.

**Responsibilities**

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.



**HLB Mann Judd**  
**Chartered Accountants**

Melbourne  
2 October 2025



**Jude Lau**  
**Partner**

## Additional Information for Listed Public Companies

For the Year Ended 30 June 2025

### NSX Additional Information

Additional information required by the NSX Listing Rules and not disclosed elsewhere in this report is set out below. This information is effective as at 24 September 2025.

### Substantial shareholders

The number of substantial shareholders and their associates are set out below:

Shareholders	Number of shares
Chin Hua Pei	50,000,000
Kah Meng Lim	40,449,723
Siew Leng Seah	23,160,000

### Voting rights

#### Ordinary Shares

On a show of hands, every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

### Distribution of equity security holders

Holding	Ordinary shares	
	Total Units	Holders
1 - 1,000	-	-
1,001 - 5,000	-	-
5,001 - 10,000	166,000	30.00
10,001 - 100,000	615,000	12.00
100,000 and over	162,222,500	68.00
<b>Total</b>	<b>163,003,500</b>	<b>110.00</b>

There were NIL holders of less than a marketable parcel of ordinary shares.

### Ten largest shareholders

	Ordinary shares	
	Number held	% of issued shares
Chin Hua Peh	50,000,000	30.67
Kah Meng Lim	40,449,723	24.82
Siew Leng Seah	23,160,000	14.21
Ms Xiao Wang	7,354,206	4.51
Sah Soon Lim	6,600,000	4.05
Dr Ashraf El Masry	2,300,000	1.41
Cell Differentiation Hub Pte Ltd	2,000,000	1.23
Mr Chee Hua Tan	1,950,000	1.20
Mr Aldo Aditya Widodo	1,750,000	1.07
Mr Voon Kwong Tien	1,506,500	0.92
	<b>137,070,429</b>	<b>84.09</b>



## **Additional Information for Listed Public Companies**

### **For the Year Ended 30 June 2025**

#### **Results of the Group for the last 5 years**

As specified in the NSX Listing Rules 6.9(9), a summary table of the Group's for the last five years is required to be disclosed, however, as the Group was incorporated on 22 December 2023, the information contained within the financial report provides sufficient comparison of the Group's results for full year and period since incorporation.

#### **Shareholder dividend arrangements**

No shareholder of the Company has waived or agreed to waive any dividends during the financial year. The Company did not declare any dividends for the year ended 30 June 2025 (2024: nil).

#### **Securities exchange**

The Company is listed on the National Stock Exchange of Australia Limited ("NSX").